key: cord-0963769-rmhb8wjd
authors: de Joode, K.; Tol, J.; Hamberg, P.; Cloos, M.; Kastelijn, E.A.; Borgers, J.S.W.; Nuij, V.J.A.A.; Klaver, Y.; Herder, G.J.M.; Mutsaers, P.G.N.J.; Dumoulin, D.W.; Oomen - de Hoop, E.; van Diemen, N.G.J.; Libourel, E.J.; Geraedts, E.J.; Bootsma, G.P.; van der Leest, C.H.; Peerdeman, A.L.; Herbschleb, K.H.; Visser, O.J.; Bloemendal, H.J.; van Laarhoven, H.W.M.; de Vries, E.G.E.; Hendriks, L.E.L.; Beerepoot, L.V.; Westgeest, H.M.; van den Berkmortel, F.W.P.J.; Haanen, J.B.A.G.; Dingemans, A.C.; van der Veldt, A.A.M.; Becker-Commissaris, A.; Terheggen, F.; van den Borne, B.E.E.M.; van Warmerdam, L.J.C.; van Leeuwen, L.; van der Meer, F.S.; Tiemessen, M.A.; van Diepen, D.M.; Strobbe, L.; Koekkoek, J.A.F.; Brocken, P.; Drooger, J.C.; Heller, R.; de Groot, J.W.B.; Stigt, J.A.; Pitz, C.C.M.; Slingerland, M.; Borm, F.J.; Haberkorn, B.C.M.; Westeinde, S.C. van 't; Aarts, M.J.B.; van Putten, J.W.G.; Youssef, M.; Cirkel, G.A.; van Rooijen, C.R.; Citgez, E.; Barlo, N.P.; Scholtes, B.M.J.; Koornstra, R.H.T.; Claessens, N.J.M.; Faber, L.M.; Rikers, C.H.; van de Wetering, R.A.W.; Veurink, G.L.; Bouter, B.W.; Houtenbos, I.; Bard, M.P.L.; Douma, G.; Jalving, M.; Hiltermann, T.J.N.; Schuurbiers - Siebers, O.C.J.; Suijkerbuijk, K.P.M.; van Lindert, A.S.R.; van de Wouw, A.J.; van den Boogaart, V.E.M.; Bakker, S.D.; Looysen, E.; de Jong, W.K.; Siemerink, E.J.M.; Staal, A.J.; Franken, B.; van Geffen, W.H.
title: Life-prolonging treatment restrictions and outcome in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium
date: 2021-10-25
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.10.009
sha: 066b19629c7297ef1cb177c8033ce26ee73cfbc9
doc_id: 963769
cord_uid: rmhb8wjd

Aim of the study: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted cancer care. In this study, clinical patient characteristics related to COVID-19 outcome and advanced care planning, in terms of non-oncological treatment restrictions (e.g., do-not-resuscitate codes), were studied in patients with cancer and COVID-19. METHODS: The Dutch Oncology COVID-19 Consortium (DOCC) registry was launched in March 2020 in 45 hospitals in the Netherlands, primarily to identify risk factors of a severe COVID-19 outcome in patients with cancer. Here, an updated analysis of the registry was performed, and treatment restrictions (e.g., do-not-intubate codes) were studied in relation to COVID-19 outcome in patients with cancer. Oncological treatment restrictions were not taken into account. RESULTS: Between March 27(th), 2020, and February 4(th), 2021, 1360 patients with cancer and COVID-19 were registered. Follow-up data of 830 patients could be validated for this analysis. Overall, 230 out of 830 (27.7%) patients died of COVID-19, and 60% of the remaining 600 patients with resolved COVID-19 were admitted to the hospital. Patients with haematological malignancies or lung cancer had a higher risk of a fatal outcome than other solid tumours. No correlation between anti-cancer therapies and the risk of a fatal COVID-19 outcome was found. In terms of end-of-life communication, 50% of all patients had restrictions regarding life-prolonging treatment (e.g., do-not-intubate codes). The majority of the identified patients with treatment restrictions had risk factors associated with fatal COVID-19 outcome. CONCLUSION: There was no evidence of a negative impact of anti-cancer therapies on COVID-19 outcome. Timely end-of-life communication as part of advanced care planning could save patients from prolonged suffering and decrease burden in intensive care units. Early discussion of treatment restrictions should therefore be part of routine oncological care, especially during the COVID-19 pandemic.

The Dutch Oncology COVID-19 Consortium (DOCC) registry was launched in March 2020 in 45 49 hospitals in the Netherlands, primarily to identify risk factors of a severe COVID-19 outcome in 50 patients with cancer. Here, an updated analysis of the registry was performed, and treatment 51 restrictions (e.g., do-not-intubate codes) were studied in relation to COVID-19 outcome in 52 patients with cancer. Oncological treatment restrictions were not taken into account. The coronavirus disease 2019 pandemic overwhelmed healthcare systems worldwide 81 [1] . Early reports from China showed an increased risk of a more severe course of COVID-19 in 82 patients with cancer [2, 3] , which has led to adjustments in oncological treatment [4, 5] . To date, 83 the pandemic has significantly impacted cancer care [4, 5] . 84 The Dutch Oncology COVID-19 Consortium (DOCC) was initiated in March 2020. The main 85 objective of this registry was to identify risk factors of a severe course of COVID-19 in patients 86 with cancer. In September 2020, the first analysis was published [6] . Since then, the number of 87 patients with cancer and COVID-19 in the Netherlands has increased rapidly. Although risk factors 88 for these patients leading to a severe course of COVID-19 have partly been elucidated (e.g., age, 89 male sex, haematological malignancies, and lung cancer) [6-10], uncertainties regarding specific 90 risks, especially regarding the safety of continuing cancer treatment, remain [11, 12] . 91 More knowledge of specific risks for patients with cancer could guide physicians to make 92 informed decisions on continuing oncological treatment and treatment restrictions in case of 93 severe independently, subgroup analyses were performed. The indication of steroid use was 136 categorised in the following two groups: steroid use as part of the anti-cancer treatment regimen 137 (e.g., as anti-emetic treatment) vs. steroid use not related to the anti-cancer treatment regimen. 138 In addition, duration of steroid use was categorised as either <7 days or ≥7 days. As topical 139 steroids are expected to have minimal systemic effects, and inhaled steroids are suggested to 140 have beneficial effects [21] on COVID-19 outcome, these types were excluded from this analysis. 141 In addition, hydrocortisone suppletion in patients with adrenal insufficiency was not included. 190 In univariable analysis, male sex, older age, (a history of) smoking, cardiovascular disease, chronic 191 obstructive pulmonary disease, diabetes mellitus, prior/other malignancy, and treatment with 192 steroids before COVID-19 were all associated with a higher risk of fatal COVID-19 outcome (Table   193 2). In addition, lung cancer and haematological malignancies were associated with an increased 194 risk of fatal outcome compared to other solid tumours (Table 2 ). In multivariable analysis, age, (Table 3) . Treatment with targeted therapy (e.g., 207 trastuzumab, bevacizumab, and palbociclib) was associated with a decreased risk of a fatal 208 COVID-19 outcome. The administered targeted therapies are presented in Supplementary Table   209 2. In multivariable analysis, age, cardiovascular disease, prior/other malignancy, and presence of Table   260 2). As the effect was not significant in a multivariable model within the active treatment group, 261 it is conceivable that the effect of targeted therapy is caused by multicollinearity. Treatment with 262 trastuzumab +/-pertuzumab is usually administered to patients with breast cancer, a population should not be of great concern, as the main objective of this registry was to identify risk factors 295 for a severe course of COVID-19 in patients with cancer. 296 Over a year into the COVID-19 pandemic, its impact on oncological healthcare is still significant. Resolved 460 

Clinical characteristics of coronavirus disease 311 2019 in China

Clinical characteristics of COVID-19-infected A

The Netherlands; 2 Department of Internal Medicine, Bravis 462 Hospital

The 464 Netherlands; 5 Department of Internal Medicine

The Netherlands; 10 Department of Pulmonary 469 Diseases, Haga Ziekenhuis, Den Haag

The Netherlands; 16 Department of Medical Oncology

Maasstad 476 Hospital

The Netherlands; 25 Department of Pulmonary Medicine

The Netherlands; 26 Department of Respiratory Medicine

The 485 Netherlands; 28 Department of Internal Medicine, Rijnstate ziekenhuis

The Netherlands; 30 Department of 487 Internal Medicine, Rode Kruis Hospital

The 490 Netherlands; 34 Department of Pulmonology

Department of Pulmonary Diseases, Treant Zorggroep, 493 Scheper hospital

The 504 Netherlands; 49 Department of Pulmonary Diseases

The authors want to thank all the oncology physicians and healthcare staff for their participation 401 in the DOCC registry during this COVID-19 pandemic. The authors thank the clinical trial center

at the Erasmus MC, and in particular S. Aammari, for the administrative support. 403 The role of the funding source 404 This study was supported by a grant from the Dutch Cancer Society, a non-profit organisation. 405 The Dutch Cancer Society had no role in study design, data collection, data analysis, data 406 interpretation, or writing of the report.